Torax® Medical Inc. has received CE Mark for its FENIX™ Continence Restoration System, an innovative new approach to the treatment of fecal incontinence. Fecal Incontinence (FI) is the inability to control bowel movements. The symptoms can vary in severity and frequency. While studies suggest FI is more prevalent in women and increases with age, men and women of all ages can be affected and for these people there are few treatment options. Torax Medical anticipates first commercial implants in November at specialized medical centers in Europe.
“The FENIX Continence Restoration System represents a promising new treatment option for patients suffering from this debilitating problem. We plan to work with medical centers which specialize in the treatment of fecal incontinence as we introduce the FENIX System in European markets.”
Todd Berg, CEO of Torax Medical, commented, "The FENIX Continence Restoration System represents a promising new treatment option for patients suffering from this debilitating problem. We plan to work with medical centers which specialize in the treatment of fecal incontinence as we introduce the FENIX System in European markets."
"The FENIX system provides another therapeutic alternative for my patients with this difficult condition. In studying this technology for the past 3 years, I've become comfortable with its clinical results and its potential benefits for various patient groups. The FENIX System offers a minimally invasive approach, begins functioning immediately and requires no adjustments by either the physician or the patient. I look forward to incorporating it as part of my routine clinical practice," said Professor Paul-Antoine Lehur of University Hospital of Nantes, France.
High-sensitivity wastewater surveillance correlates with COVID-19 infections